NCT01918332View on ClinicalTrials.gov

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

PHASE3CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Hypertension,Hyperlipidemia

Interventions

DRUG

Valsartan 160mg

DRUG

Rosuvastatin 20mg

DRUG

Valsartan 160mg placebo

DRUG

Rosuvastatin 20mg placebo

Trial Locations (1)

Unknown

Yonsei University Health System Severance Hospital, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01918332 - Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia | Biotech Hunter | Biotech Hunter